A Study of rTMS Personalized Precision Treatment of Post-stroke Depression
A Study of rTMS Personalized Precision Treatment of Post-stroke Depression
This is a multicenter, randomized trial aims to reveal the efficacy and safety of Repetitive
 transcranial magnetic stimulation (rTMS) individualized therapy based on the 'emotional loop
 destabilization' mechanism of PSD .One hundred and twenty participants will be recruited from
 three centers and randomized with a 1:1 ratio to receive "Personalized" rTMS treatment or
 traditional rTMS treatment in addition to routine antidepressant treatments.The data of
 neuropsychological tests and MRI will be collected at 0, 2，4 and 8 weeks after the
 commencement of the treatment.
This is a multicenter, randomized trial aims to reveal the efficacy and safety of rTMS
 individualized therapy based on the 'emotional loop destabilization' mechanism of PSD .One
 hundred and twenty participants will be recruited from three centers and randomized with a
 1:1 ratio to receive "Personalized" rTMS treatment or traditional rTMS treatment in addition
 to routine antidepressant treatments.

 Based on inclusion and exclusion criteria, after stroke depression (post-stroke depression,
 PSD) cases were collected and randomized into two groups: "individualized" rTMS+ drug
 treatment group and traditional rTMS plus traditional drug treatment group. The main
 indicators were the effective rate of treatment.Based on inclusion and exclusion criteria,
 after stroke depression (post-stroke depression, PSD) cases were collected and randomized
 into two groups: "individualized" rTMS+ drug treatment group and traditional rTMS plus
 traditional drug treatment group. The main indicators were the effective rate of treatment.
 The primary outcome is the measurement of 24-item Hamilton Depression Rating Scale (HAMD-24)
 scores, the secondary outcomes include National Institutes of Health Stroke Scale (NIHSS),
 Activities of Daily Living Scale (ADLs),self-rating anxiety scale(SAS). The record of the
 adverse reactions and sequelae during treatment and follow-up, with a view to providing a
 better clinical method for the treatment of PSD.
Inclusion Criteria

 （1） First-time ischemic stroke with clinical and MRI or CT findings of basal ganglia stroke
 (ICD-10-CM code 293.83[F06.32]) (3) Right-handedness (4)Clear consciousness (5)Aged 25-75
 years with a recent (less than 24 months) ischemic stroke;

 Exclusion Criteria

 1. Aphasia or severe cognitive impairment, severe hearing impairment;

 2. Contraindications of MRI scan and rTMS treatment such as pacemaker implantation;
 (3)Depression caused by psychoactive substances and non addictive substances;（4）Prior
 history of depressive disorders or major trauma within 1 year, severe depression or
 any other severe mental disorders;

 （5）Pregnant or breast-feeding women; （6）Refusal to sign informed consent of this study